Comparing of Affimed N.V. (AFMD) and MannKind Corporation (NASDAQ:MNKD)

Since Affimed N.V. (NASDAQ:AFMD) and MannKind Corporation (NASDAQ:MNKD) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. 3 0.00 51.18M -0.17 0.00
MannKind Corporation 1 -0.12 184.08M -0.41 0.00

In table 1 we can see Affimed N.V. and MannKind Corporation’s gross revenue, earnings per share and valuation.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Affimed N.V. 1,899,988,862.90% -22.7% -11.2%
MannKind Corporation 14,619,966,642.84% 0% 0%

Volatility & Risk

Affimed N.V. has a 2.79 beta, while its volatility is 179.00% which is more volatile than Standard and Poor’s 500. MannKind Corporation’s 2.29 beta is the reason why it is 129.00% more volatile than Standard and Poor’s 500.


Affimed N.V. has a Current Ratio of 3.2 and a Quick Ratio of 3.2. Competitively, MannKind Corporation’s Current Ratio is 0.9 and has 0.8 Quick Ratio. Affimed N.V.’s better ability to pay short and long-term obligations than MannKind Corporation.

Insider & Institutional Ownership

The shares of both Affimed N.V. and MannKind Corporation are owned by institutional investors at 41.7% and 27.4% respectively. About 8.15% of Affimed N.V.’s share are held by insiders. Competitively, 0.3% are MannKind Corporation’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. 2.74% 1.01% -11.76% -10.18% 71.43% -3.54%
MannKind Corporation -0.88% 0% -23.81% -8.94% -23.81% 5.66%

For the past year Affimed N.V. had bearish trend while MannKind Corporation had bullish trend.


On 6 of the 10 factors MannKind Corporation beats Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.